26 Mar 2012 07:00
26 March 2012
Ark Therapeutics Group PLC
Broker Change of Name
Ark Therapeutics Group plc (AKT.L) announces that its Broker, Collins Stewart Europe Limited, has changed its name to Canaccord Genuity Limited with immediate effect. This follows the completion of the acquisition of Collins Stewart Hawkpoint plc by Canaccord Financial Inc.
-Ends-
Enquiries:
Ark Therapeutics Group plc | Tel: 020 7388 7722 |
Iain Ross, Executive Chairman | |
Martyn Williams, Chief Executive Officer | |
Russell Banks, Chief Financial Officer | |
Canaccord Genuity Limited | Tel: 020 7523 8000 |
Jamie Adams / Lucy Tilley | |
FTI Consulting | Tel: 020 7831 3113 |
Ben Atwell / Susan Quigley |
Ark Therapeutics Group plc
Ark Therapeutics Group plc is a specialist healthcare group (the "Group") addressing high value areas of unmet medical need within vascular disease and cancer. These are large and growing markets, where opportunities exist for effective new products to generate significant revenues.
Ark has an early stage pipeline emanating from collaborations with University College, London and the AI Virtanen Institute in Kuopio, Finland, the development of which it intends to progress in collaboration with pharmaceutical and biotech partners.
In addition Ark has the ability to off-set a proportion of its R&D costs and to generate sustainable revenues through the exploitation of its proprietary technology platform, process development, scale-up and manufacturing capabilities on behalf of third parties.
Ark has its origins in businesses established in the mid-1990s by Professor John Martin of University College London and Professor Seppo Ylä-Herttuala of the AI Virtanen Institute at the University of Kuopio, Finland, both of whom remain consultants on the Company's research and development programmes.
Ark's shares were first listed on the London Stock Exchange in March 2004 (AKT.L).